Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...

Global Blood Therapeutics novel sickle cell disease drug, Oxbryta, continues to outperform revenue expectations early in its launch despite the "pandemic era". It is evident in both the data and ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

Global Blood Therapeutics is on track to start a Phase II study by mid-year. So, it is possible that Oxbryta’s biggest competition is actually in-house. GBT Pipeline (GBT) ...

Pfizer will spend about $5.4 billion to buy Global Blood Therapeutics as the pharmaceutical giant continues to invest some of the cash influx reaped during the COVID-19 pandemic.

Shares of Global Blood Therapeutics, a biotech working on a treatment for sickle cell disease, shot up to $43.11 a share on Wednesday after the company's $120 million IPO topped its target range ...

The global blood cancer therapeutics market is poised to grow by USD 12.63 billion during 2019-2023, progressing at a CAGR of over 8%.

The all-cash deal will see Pfizer acquire all outstanding shares of Global Blood Therapeutics for $68.50 per share; all told, the enterprise value of the arrangement is roughly $5.4 billion.

Shares of rare-disease specialist Global Blood Therapeutics (GBT) are rising sharply for the second day in a row. As of 12:38 p.m. ET, the drugmaker's stock was up by a healthy 38.4%.

Global Blood Therapeutics provided investors with a preliminary update from its phase 3 HOPE study. This 154-patient trial is testing its drug Voxelotor as a treatment for kids with sickle cell ...

In response to receiving Breakthrough Therapy Designation from the FDA on the company's lead compound, shares of Global Blood Therapeutics (NASDAQ: GBT) , a clinical-stage biotech focused on blood ...